Logo

Invitrogen Offers $300M in Convertible Notes to Repay Credit Line, Possibly Fund More M&A

Jun 14, 2005

NEW YORK, June 14 (GenomeWeb News) - Invitrogen said yesterday that it intends to offer $300 million of senior convertible notes due 2025.

 

Invitrogen said that purchasers of the notes will have an option to purchase up to an additional $50 million to cover over-allotments.

 

The company said it will use some of the net proceeds of the offering to repay around $124 million borrowed a revolving line of credit with Bank of America.

 

Invitrogen said it intends to use the balance of the net proceeds for "potential acquisitions and for general corporate purposes, including the potential repayment or redemption of other outstanding debt."

Breaking News
The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.